• Home
  •  / Amicus Therapeutics

Amicus Therapeutics

OverviewSuggest Edit

Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.

TypePublic
Founded2002
HQPhiladelphia, PA, USMap
Websiteamicusrx.com
Employee Ratings3.3More
Overall CultureC+More
View Jobs (29)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)584(+15%)
Job Openings29
Revenue (FY, 2020)$260.9 M(+44%)
Share Price (Jun 2021)$10.1(+7%)
Cybersecurity ratingBMore

Key People/Management at Amicus Therapeutics

John F. Crowley

John F. Crowley

Chairman and Chief Executive Officer
Margaret G. McGlynn

Margaret G. McGlynn

Director
Robert Essner

Robert Essner

Director
Lynn D. Bleil

Lynn D. Bleil

Director
Burke W. Whitman

Burke W. Whitman

Director
Craig A. Wheeler

Craig A. Wheeler

Director
Show more

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Philadelphia, Northbridge, Pointe-Claire, Paris and in 7 other locations
Philadelphia, PA, US (HQ)
3675 Market St
Northbridge, AU
21 Dorset Rd
Pointe-Claire, CA
6500 TransCanada Service Rd, 4th Floor
Paris, FR
12 Place de la Défense
München, DE
Willy-Brandt-Platz
Dublin, IE
Block 1, Blanchardstown Corporate Park, Ballycoolin Rd, Ballycoolen
Show all (11)

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Revenue

Amicus Therapeutics's revenue was reported to be $260.89 m in FY, 2020
USD

Revenue (Q1, 2021)

66.4m

Gross profit (Q1, 2021)

59.9m

Gross profit margin (Q1, 2021), %

90.2%

Net income (Q1, 2021)

(65.7m)

EBIT (Q1, 2021)

(53.1m)

Market capitalization (7-Jun-2021)

2.7b

Closing stock price (7-Jun-2021)

10.1

Cash (31-Mar-2021)

184.8m

EV

2.9b
Amicus Therapeutics's current market capitalization is $2.7 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

21.4m18.4m363.0k1.2m5.0m36.9m91.2m182.2m260.9m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m14.4m22.0m31.0m

Gross profit

4.1m30.7m76.8m160.3m229.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.0m5.8m7.8m10.6m39.0k456.0k475.0k293.0k2.1m4.2m7.2m10.9m16.7m21.3m20.6m34.0m44.1m48.8m60.5m62.4m67.4m66.4m

Cost of goods sold

344.0k775.0k1.1m1.8m2.6m3.1m4.3m4.1m5.4m5.6m6.6m6.7m8.4m6.5m

Gross profit

1.8m3.4m6.1m9.1m14.1m18.2m16.3m30.0m38.8m43.2m54.0m55.7m59.0m59.9m

Gross profit Margin, %

84%81%85%84%84%85%79%88%88%89%89%89%88%90%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

25.7m34.0m43.6m24.1m69.5m187.0m49.1m79.7m142.8m163.2m

Accounts Receivable

5.0m3.2m759.0k1.3m9.5m22.0m33.3m46.9m

Prepaid Expenses

5.9m2.3m5.5m2.9m2.6m19.3m16.6m20.0m29.7m

Inventories

3.4m4.6m8.4m14.0m19.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

25.8m22.8m24.5m28.9m24.3m26.7m23.5m30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m96.3m220.6m166.3m123.2m164.6m210.6m184.8m

Accounts Receivable

2.0m3.8m4.3m7.2m3.2m1.3m1.0m2.1m38.0k475.0k293.0k864.0k1.9m3.8m6.0m10.8m15.1m14.2m23.0m28.7m33.7m40.6m43.0m44.8m44.9m

Prepaid Expenses

3.1m3.0m2.8m2.7m3.1m1.8m2.0m1.7m1.8m951.0k1.8m2.5m3.6m3.5m2.7m3.3m5.2m10.8m6.0m6.2m10.6m14.4m16.2m13.6m20.1m19.6m15.7m18.3m15.6m21.7m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m8.2m10.4m9.2m12.8m13.0m15.8m18.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(44.4m)(48.8m)(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)(356.4m)(276.9m)

Depreciation and Amortization

1.6m1.7m1.7m1.5m1.8m3.2m3.6m4.2m4.8m8.8m

Inventories

(3.7m)(897.0k)(4.2m)(5.1m)(4.6m)

Accounts Payable

1.4m(863.0k)(613.0k)6.2m15.5m7.1m12.6m17.1m46.7m(10.6m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(26.0m)(35.7m)(13.1m)(22.5m)(38.8m)(17.5m)(32.8m)(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)(120.3m)(204.8m)(266.7m)(88.9m)(141.4m)(205.5m)(65.7m)

Depreciation and Amortization

864.0k1.2m420.0k862.0k1.3m439.0k889.0k1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m991.0k2.1m3.3m1.8m3.8m6.3m1.6m

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)345.0k(1.9m)(2.0m)(251.0k)1.4m2.2m741.0k

Accounts Payable

(1.3m)(192.0k)(1.3m)(641.0k)(280.0k)(2.4m)173.0k(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)(4.3m)13.0m(10.3m)(11.8m)3.7m(8.9m)12.5m8.7m(35.3m)(23.9m)(23.4m)(40.2m)
show all
USDQ2, 2011

Financial Leverage

2 x
Show all financial metrics

Amicus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about our premium products
SecurityScorecard logo

Amicus Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Amicus Therapeutics Online and Social Media Presence

Amicus Therapeutics's Trends

Embed Graph

Amicus Therapeutics Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    A+

    100/100

  • Compensation

    D

    55/100

Learn more on Comparably

Amicus Therapeutics News and Updates

June 08, 2021

Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA

Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK
May 28, 2021

Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually on Wednesday, June 9, 2021 at …
May 21, 2021

Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases

PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May 21-22 and 28-29, 202…
May 10, 2021

Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

Galafold® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
May 07, 2021

Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May:
May 06, 2021

Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme
Show more

Amicus Therapeutics Blogs

February 11, 2021

Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021 Patients switching to AT-GAA from the approved standard of care ERT (alglucosidase alfa) walked on average 17 meters farther (p=0.046) Patients switching to
February 08, 2021

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies to Develop Next Generation Gene Therapies PHILADELPHIA, Feb.
January 05, 2021

Craig A. Wheeler

Craig A. Wheeler Matthew.Callan… Tue, 01/05/2021 - 17:44 Member of the Compensation and Leadership Committee Chair of the Science and Technology Committee Craig A. Wheeler Director Director Since January 1, 2016 …
January 05, 2021

Michael A. Kelly

Michael A. Kelly Matthew.Callan… Tue, 01/05/2021 - 17:41 Member of the Science and Technology Committee Member of the Audit and Compliance Committee Michael A. Kelly Director Director Since January 1, 2020 …
January 05, 2021

Bradley L. Campbell

Bradley L. Campbell Matthew.Callan… Tue, 01/05/2021 - 17:27 Bradley L. Campbell Director Director Since January 1, 2018
November 05, 2020

Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates

Galafold 3Q20 Revenue of $67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20 Positive CLN6 Batten Disease Gene Therapy Data Presented in October Fabry Disease Gene Therapy Clinical Candidate
Show more

 Amicus Therapeutics Frequently Asked Questions

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Who are Amicus Therapeutics key executives?

    Amicus Therapeutics's key executives are John F. Crowley, Margaret G. McGlynn and Robert Essner.

  • How many employees does Amicus Therapeutics have?

    Amicus Therapeutics has 584 employees.

  • What is Amicus Therapeutics revenue?

    Latest Amicus Therapeutics annual revenue is $260.9 m.

  • What is Amicus Therapeutics revenue per employee?

    Latest Amicus Therapeutics revenue per employee is $446.7 k.

  • Who are Amicus Therapeutics competitors?

    Competitors of Amicus Therapeutics include Modis Therapeutics, Sanofi Genzyme and PhaseBio Pharmaceuticals.

  • Where is Amicus Therapeutics headquarters?

    Amicus Therapeutics headquarters is located at 3675 Market St, Philadelphia.

  • Where are Amicus Therapeutics offices?

    Amicus Therapeutics has offices in Philadelphia, Northbridge, Pointe-Claire, Paris and in 7 other locations.

  • How many offices does Amicus Therapeutics have?

    Amicus Therapeutics has 11 offices.